- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02412462
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
June 27, 2017 updated by: Alethia Biotherapeutics
A Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AB-16B5 in Subjects With an Advanced Solid Malignancy
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy.
AB-16B5 is a humanized monoclonal antibody that inhibits the activity of the secreted form of clusterin (sCLU), a potent inducer of the epithelial-to-mesenchymal transition (EMT).
Eligible subjects will have a disease that has been refractory to prior therapy and is unlikely to benefit from known therapies.
Study Overview
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with a histologically or cytologically confirmed advanced solid malignancy that has been refractory to prior therapy and is unlikely to benefit from known therapies.
- Subjects may have measurable or non-measurable but evaluable disease.
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 and an estimated life expectancy of at least 12 weeks.
- Subjects must be ≥ 18 years old.
- Male, or female subjects who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile. Females of childbearing potential with a negative serum pregnancy test prior to entering the study and using adequate forms of contraception for the duration of the study, including 30 days after the last treatment. Males should avoid fathering children during the course of the study, and adequate methods of contraception should be used by both male and female subjects. Subjects and their partners with reproductive potential must use an effective contraceptive method while the subject is on the study treatment and for 30 days after the last treatment.
Subjects must have adequate organ and immune function as indicated by the following laboratory values:
- ANC ≥ 1.5 X 109/L
- Platelets > 100 X 109/L
- Hemoglobin ≥ 90 g/L
- Serum creatinine ≤ 132 µmol/L
- Total Bilirubin ≤ 1.5 X ULN
AST (SGOT) and ALT (SGPT) ≤ 3 X ULN* or;
5 X ULN* (if hepatic metastases present)
- ULN: Institution's upper limit of normal
- Subjects enrolled in the standard dose escalation portion of the study must have a tumor lesion amenable for biopsy with no contraindications for biopsy.
- Subjects must understand and be able and willing and likely to fully comply with the study procedures, including scheduled follow-up, and restrictions.
- Subjects must have given written personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines, before completing any study related procedures.
Exclusion Criteria:
- Subjects with medical, social, or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
- Prior cancer therapy including surgery, radiotherapy, chemotherapy, hormonal and biological therapies within 3 weeks prior to study treatment.
- Uncontrolled brain metastases.
- Uncontrolled infection.
- Clinically significant ECG abnormalities.
- Known hypersensitivity of Grade > 2 to previous monoclonal antibody therapy.
- History of alcohol or other substance abuse within the last year.
- Use of another investigational agent in a clinical trial within the last 4 weeks prior to study treatment.
- Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening must be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AB-16B5
Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion.
One cycle of treatment will consist of 21 days.
The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with an adverse event as a measure of safety and tolerability
Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
|
Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determination of plasma concentrations of AB-16B5
Time Frame: Several time-points during Cycle 1 and Cycle 2 for a total of 6 weeks
|
Several time-points during Cycle 1 and Cycle 2 for a total of 6 weeks
|
Objective tumor responses in subjects with measurable disease according to RECIST
Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
|
Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
|
Monitoring of epithelial-to-mesenchymal (EMT) and stem cells biomarkers in peripheral blood circulating tumor cells and paired tumor biopsies
Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
|
Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
March 30, 2015
First Submitted That Met QC Criteria
April 6, 2015
First Posted (Estimate)
April 9, 2015
Study Record Updates
Last Update Posted (Actual)
June 28, 2017
Last Update Submitted That Met QC Criteria
June 27, 2017
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AB-16B5-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on AB-16B5
-
Alethia BiotherapeuticsRecruitingMetastatic Colorectal CancerCanada
-
Alethia BiotherapeuticsCompletedNSCLC Stage IVUnited States, Canada
-
AB Biotics, SACompletedModerate HypercholesterolemiaFrance
-
AnHeart Therapeutics Inc.Recruiting
-
Armata Pharmaceuticals, Inc.No longer available
-
Angiocrine BioscienceCalifornia Institute for Regenerative Medicine (CIRM)CompletedHodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
Armata Pharmaceuticals, Inc.No longer available
-
Smart Medical Systems Ltd.UnknownInflammatory Bowel Diseases | Crohn Disease | Colitis, UlcerativeIsrael
-
Asklepios Biopharmaceutical, Inc.RecruitingMuscular Dystrophy | Limb Girdle Muscular Dystrophy | LGMD2I | LGMD | Limb-Girdle Muscular Dystrophy Type 2 | LGMD2 | FKRP | FKRP Mutation | Fukutin Related ProteinUnited States
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand